Financing
Payments to Noncontrolling Interests
Royalty Pharma Payments to Noncontrolling Interests decreased by 2.1% to $39.88M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 25.9%, from $53.83M to $39.88M. Over 3 years (FY 2022 to FY 2025), Payments to Noncontrolling Interests shows an upward trend with a 5.1% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
First reportedQ1 2018
Last reportedQ1 2026May 6, 2026
Metric ID:
financing_payments_to_minority_shareholdersHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $112.48M | $125.43M | $34.52M | $37.83M | $38.62M | $33.15M | $33.39M | $30.53M | $31.12M | $24.49M | $32.01M | $30.68M | $31.02M | $31.45M | $53.83M | $38.61M | $34.28M | $40.76M | $39.88M |
| QoQ Change | — | +11.5% | -72.5% | +9.6% | +2.1% | -14.2% | +0.7% | -8.6% | +1.9% | -21.3% | +30.7% | -4.2% | +1.1% | +1.4% | +71.2% | -28.3% | -11.2% | +18.9% | -2.1% |
| YoY Change | — | — | — | -66.4% | -69.2% | — | -3.2% | -19.3% | -19.4% | -26.1% | -4.1% | +0.5% | -0.3% | +28.4% | +68.2% | +25.8% | +10.5% | +29.6% | -25.9% |
Range$24.49M – $125.43M
CAGR-20.6%
Avg YoY Growth-4.7%
Median YoY Growth-3.2%
Payments to Noncontrolling Interests at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's payments to noncontrolling interests?
- Royalty Pharma (RPRX) reported payments to noncontrolling interests of $39.88M in Q1 2026.
- How has Royalty Pharma's payments to noncontrolling interests changed year-over-year?
- Royalty Pharma's payments to noncontrolling interests decreased by 25.9% year-over-year, from $53.83M to $39.88M.
- What is the long-term trend for Royalty Pharma's payments to noncontrolling interests?
- Over 3 years (2022 to 2025), Royalty Pharma's payments to noncontrolling interests has grown at a 5.1% compound annual growth rate (CAGR), from $144.12M to $167.48M.